Inventor · disambiguated record
Marc Mansour
Also filed as: MANSOUR MARC
18 granted patents·10 pending applications·90 citations·filing 2003–2022
92Inventor score
Top patents by PatentIndex Score
28 records- 0195US10272042B2Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatmentIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Apr 30, 2019·41 cites·61 claims
- 0287US7056515B2Antigens for immunocontraceptionIMMUNOVACCINE TECHNOLOGIES INC·Filed 2003·Granted Jun 6, 2006·18 cites·19 claims
- 0384US10232052B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Mar 19, 2019·4 cites·27 claims
- 0483US11235069B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Feb 1, 2022·1 cites·27 claims
- 0583US9498493B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoMANSOUR MARC·Filed 2008·Granted Nov 22, 2016·10 cites·19 claims
- 0682US10729766B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Aug 4, 2020·1 cites·28 claims
- 0782US9925142B2Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatmentIMMUNOVACCINE TECHNOLOGIES INC·Filed 2015·Granted Mar 27, 2018·4 cites·6 claims
- 0879US10988500B2Lipid A mimics, methods of preparation, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Apr 27, 2021·1 cites·22 claims
- 0979US10105435B2Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2012·Granted Oct 23, 2018·5 cites·20 claims
- 1076US12269880B2LAG3 binding peptidesLEIDOS INC·Filed 2022·Granted Apr 8, 2025·0 cites·12 claims
- 1176US11406705B2Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjectsIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Aug 9, 2022·2 cites·20 claims
- 1270US10022441B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2013·Granted Jul 17, 2018·1 cites·29 claims
- 1369US2021322573A1Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1467US12042537B2Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjectsBIOVAXYS INC·Filed 2022·Granted Jul 23, 2024·0 cites·19 claims
- 1567US11407829B2LAG3 binding peptidesLEIDOS INC·Filed 2020·Granted Aug 9, 2022·0 cites·6 claims
- 1666US11160861B2Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvantIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Nov 2, 2021·1 cites·28 claims
- 1766US10533033B2Lipid A mimics, methods of preparation, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2015·Granted Jan 14, 2020·1 cites·35 claims
- 1865US11717563B2Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substanceIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Aug 8, 2023·0 cites·26 claims
- 1965US11077184B2Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune responseIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Aug 3, 2021·0 cites·21 claims
- 2065US2011070298A1Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic SubstanceIMMUNOVACCINE TECHNOLOGIES INC·Filed 2009·Application pending·0 cites
- 2164US2021052724A1Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 2264US2021308252A1Liposome compositions comprising pam2cys or pam3cys adjuvant and methods for inducing a humoral immune responseIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 2361US2024374727A1Binding domainUCL BUSINESS LTD·Filed 2022·Application pending·0 cites
- 2460US2010209452A1Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2008·Application pending·0 cites
- 2558US2022001010A1Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvantIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 2654US2009297593A1Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase as a Vehicle for Cancer TreatmentIMMUNOVACCINE TECHNOLOGIES INC·Filed 2006·Application pending·0 cites
- 2754US2023137174A1Novel salmonella-based coronavirus vaccineNEC ONCOIMMUNITY AS·Filed 2021·Application pending·0 cites
- 2840US2018162913A1Methods for potentiating an immune response using depot-forming and non-depot-forming vaccinesIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marc Mansour files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →